SEC Company Response from Virax Biolabs Group (VRAX) — Dec 29, 2025
Virax Biolabs Group Ltd
Date: Dec. 29, 2025 · CIK: 0001885827 · Accession: 0001193125-25-335379
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-292241
Letter
Re: Virax Biolabs Group Limited
Virax Biolabs Group Limited BioCity Glasgow Bo'Ness Road Newhouse Lanarkshire, ML1 SUH United Kingdom VIA EDGAR December 29, 2025 U.S. Securities & Exchange Commission Office of Life Sciences Division of Corporation Finance 100 F Street, NE Attn: Jessica Dickerson
Registration Statement on Form F-3
Filed December 18, 2025
File No. 333-292241
Pursuant to Rule 461 under the Securities Act of 1933, as amended, Virax Biolabs Group Limited hereby requests acceleration of effectiveness of the above referenced Registration Statement so that it will become effective at 4:00 p.m., Eastern Time, on December 30, 2025, or as soon as thereafter practicable.
Very truly yours,
/s/ James Foster
Show Raw Text
CORRESP 1 filename1.htm CORRESP Virax Biolabs Group Limited BioCity Glasgow Bo'Ness Road Newhouse Lanarkshire, ML1 SUH United Kingdom VIA EDGAR December 29, 2025 U.S. Securities & Exchange Commission Office of Life Sciences Division of Corporation Finance 100 F Street, NE Attn: Jessica Dickerson Re: Virax Biolabs Group Limited Registration Statement on Form F-3 Filed December 18, 2025 File No. 333-292241 Pursuant to Rule 461 under the Securities Act of 1933, as amended, Virax Biolabs Group Limited hereby requests acceleration of effectiveness of the above referenced Registration Statement so that it will become effective at 4:00 p.m., Eastern Time, on December 30, 2025, or as soon as thereafter practicable. Very truly yours, /s/ James Foster James Foster Chief Executive Officer